With the accumulation of convincing evidence, neoadjuvant immunochemotherapy demonstrates remarkable effectiveness in NSCLC without EGFR/ALK alterations, which has been gradually applied in clinical practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.